<DOC>
	<DOC>NCT02759042</DOC>
	<brief_summary>The primary objective is to provide continued access to PRO 140 to a subject who has completed participation in PRO140_CD02.</brief_summary>
	<brief_title>An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study</brief_title>
	<detailed_description>This is an open label, single center study designed to provide continued access to PRO 140 to a subject who have completed participation in PRO140_CD02 and continue to receive clinical benefit. The subject will receive weekly PRO 140 SC injection along with oral ART regimen during the Treatment Phase. The study treatment (PRO 140 SC injections) will be administered by a qualified medical professional or self-administered by the subject.</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>HIV Antibodies</mesh_term>
	<mesh_term>PRO-140 monoclonal antibody</mesh_term>
	<criteria>This study will recruit one treatmentexperienced, HIV1 infected patient with CCR5tropic virus, who has participated in PRO 140_CD02 clinical trial and is continuing to derive clinical benefit from PRO 140 treatment.</criteria>
	<gender>Male</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>56 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>